Afrikaans
Akan
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Basque
Belarusian
Bemba
Bengali
Bihari
Bosnian
Breton
Bulgarian
Cambodian
Catalan
Cebuano
Cherokee
Chichewa
Chinese (Simplified)
Chinese (Traditional)
Corsican
Croatian
Czech
Danish
Esperanto
Estonian
Ewe
Faroese
Filipino
Finnish
French
Frisian
Ga
Galician
Georgian
German
Greek
Guarani
Gujarati
Haitian Creole
Hausa
Hawaiian
Hebrew
Hindi
Hmong
Hungarian
Igbo
Indonesian
Interlingua
Irish
Italian
Javanese
Kannada
Kazakh
Kinyarwanda
Kirundi
Kongo
Korean
Krio (Sierra Leone)
Kurdish
Kurdish (Soranรฎ)
Kyrgyz
Laothian
Latin
Latvian
Lingala
Lithuanian
Lozi
Luganda
Luo
Luxembourgish
Macedonian
Malagasy
Malay
Malayalam
Maltese
Maori
Marathi
Mauritian Creole
Moldavian
Mongolian
Myanmar (Burmese)
Montenegrin
Nepali
Nigerian Pidgin
Northern Sotho
Norwegian
Norwegian (Nynorsk)
Occitan
Oriya
Oromo
Pashto
Persian
Polish
Portuguese (Brazil)
Punjabi
Quechua
Romansh
Runyakitara
Russian
Samoan
Scots Gaelic
Serbian
Serbo-Croatian
Sesotho
Setswana
Seychellois Creole
Shona
Sindhi
Sinhalese
Slovak
Slovenian
Somali
Spanish
Spanish (Latin American)
Sundanese
Swahili
Swedish
Tajik
Tamil
Tatar
Telugu
Thai
Tigrinya
Tonga
Tshiluba
Tumbuka
Turkish
Turkmen
Twi
Uighur
Ukrainian
Urdu
Uzbek
Vietnamese
Welsh
Wolof
Xhosa
Yiddish
Yoruba
Zulu
(dramatic music) (sirens blaring)
In a world on lockdown,
ambulance sirens haunt the streets
as COVID-19 patients quickly fill emergency rooms
and intensive care units.
Despite our technological prowess
and medical know-how, the newness
of this coronavirus limits health professionals' ability
to fight it for the moment.
How do you treat something
for which we don't have pharmaceutical interventions?
Treatment is really supportive.
Here it's about protecting the lungs
and the oxygen capacity until the person gets better.
Scientists feverishly research new treatments
and drug protocols,
all in an international effort to aid the body's defenses
and to turn the tide.
So we're dealing with a serious pathogen
of global significance.
This is not a short battle.
This is a long, long battle that we're going to face.
(dramatic music)
(intense music)
While the societal impact of COVID-19
may be clearly evident,
the details of what the disease does
to our bodies can be more difficult to see.
Some coronaviruses, like those that cause the common cold,
attack the upper airways of the respiratory system
and trigger into action almost like organic technology,
says infectious disease specialist, Dr. David Wheeler.
They're kind of like little mini thumb drives
that have information with a protective layer
and they don't do a thing
until you plug 'em into the computer, if you will,
and the cell then pulls in that viral message
and starts being driven by that message,
which mainly is to create more virus.
But just like the MERS
and SARS epidemics earlier this century,
a more penetrating point of attack
makes the COVID-19 virus much more dangerous.
It's in a more vulnerable part of our body,
in the lower airways, deep in the lungs and alveoli.
They go in, take over the cell machinery,
start making new virus.
They prompt the immune response
so when that immune response kicks in,
now we're down into the lungs themselves.
Early symptoms include headache,
body aches, fever and cough.
Those are the big four
and most people that get sick
have several of those.
It's once they start feeling like they're short of breath
and if they go into the emergency room
or the doctor's office
and their oxygen level is low,
then that's where we need to keep a close eye on 'em.
And what we found is that a small number
of the folks just all of a sudden
then get sick very quickly.
So increasingly, these patients need more
than a close eye.
They need supportive respiratory interventions
like those in high-demand ventilators
to help them breathe.
Well, shortness of breath is a sensation of suffocating.
When people are starting
to get a bit more short of breath like that,
sometimes they need to get moved
to the intensive care unit
and put on the breathing machine earlier
than we might in other conditions
'cause we don't want these sort of emergency sessions
where the person's struggling for breath
and where more healthcare workers could get exposed
to lots of aerosols in the air.
In some of the most extreme cases,
an even more scarce resource may be called upon
to perform the work of the lungs,
as a temporary last resort.
It's called ECMO.
Extracorporeal membrane oxygenation.
And that really, it's heart-lung bypass.
They put two cannulas in to veins
and pull blood out, oxygenate it and return it.
This was the treatment given to a man
in his late 50s
after his transfer to George Washington University Hospital,
which released stunning 3D images
of this patient's lung damage,
represented here in green,
laying bare the danger to all.
You do not need an MD after your name
to understand these images.
This is something that the general public
can take a look at and really start
to comprehend how severe the amount of damage
that this is causing to the lung tissue.
The damage that we're seeing is not isolated
to any one part of the lung.
This is severe damage to both lungs diffusely.
This man died about a week
after arriving at the GW Hospital.
A big part of what I think is killing people
is what we call multiorgan failure
as a result of the lungs going first.
And then other organs start to fail.
But what exactly causes this damage?
The answer: another medical acronym.
ARDS, or acute respiratory distress syndrome.
Inflammation in COVID-19 cases brought about
by our own immune systems stuck in overdrive.
A lot of the disease we see
in terms of virus-hosted directions,
is what we refer to as immunopatholgoy.
So it's our own immune system creating some
of the damage in particular target organs
in response to that virus.
And so it's like turning on the heat.
But if it's too much,
then you start hurting the tissues around it.
It starts to create a barrier
between where the alveoli are,
where oxygen's coming in,
and the capillaries right next to it
that are picking up that oxygen
to take it to the body
and there's a little thin membrane,
an interstitions there,
which has very little space in it
but certain kinds of interstitional pneumonia
can start to put fluid in and inflammation in that
and thicken it
so that the oxygen exchange is then compromised.
(dramatic music)
In 1918, the Spanish Flu
filled understaffed hospitals beyond capacity.
The personnel shortages, largely a result
of doctors and nurses, serving during World War I.
The effect of war socially
and politically took a huge toll on the health systems
around the world
and the hospitals that will need to provide care.
Likewise, in our battle against COVID-19,
the anticipated surge of cases presents additional hurdles,
necessitating field hospitals
and creating shortages of medical supplies
and equipment, making a bad situation even worse.
With a disease like COVID-19,
what we really have to worry about
is the strain on the health system.
(radio mumbling)
We're waiting to see is this gonna be like Milan,
where you have 50 people waiting to come into the hospital
and you have 20 ventilators
and 40 of those people need the ventilators.
But what about medicinal aids
to fight the novel coronavirus?
Despite limited and anecdotal evidence
for some drugs, public health officials continue
to warn against false hope
and await the results of scientifically sourced
and controlled testing.
There are a number of candidate therapies
that literally, as I speak to you today,
are being tested in randomized control trials.
These pharmaceutical investigations
take two primary approaches.
One targets the virus.
The other explores drugs
to control the immune response to the virus
after ARDS sets in.
What happens then is like a small-scale nuclear war
inside the body.
At late stages when it's this immunological battle,
actually killing the virus probably doesn't do
a lot of good.
It's really trying to control the immune system
that is then the key to successfully treating a patient.
Clinical researcher David Paterson
and his team at Australia's University
of Queensland mobilized to explore a combination
of both approaches.
So the objective of our trial
is really to get in early
and prevent a person needing to go into intensive care,
prevent them needing to be mechanically ventilated
and of course, prevent them from dying.
Reaching back into society's medicine cabinet,
Paterson's team hopes to potentially repurpose drugs,
originally developed to treat malaria
and antiretrovirals used in the fight against HIV/AIDS.
One of them attacks an enzyme that is very necessary
for the virus to replicate.
Another prevents the virus from attaching properly
to human cells.
We think that by inhibiting the virus,
we give the immune system time
to really take control.
The ultimate goal, to save lives,
a difficult task not only medically speaking
but also because of the challenges in gathering data
from the epicenters of this pandemic.
(nurses mumbling)
Where health systems have been overwhelmed,
a lot of practical experience is gained
but it's actually hard to do controlled trials,
for example, to determine whether a drug
is effective or whether certain interventions are effective.
Paterson's answer,
to develop a large study group
of 2,400 patients across 60 hospitals
of measure the outcomes of four different therapies.
Antiretroviral HIV drugs
and antimalarial antiviral and immunomodulator.
A combination of the two
and perhaps, most importantly, a control group.
A person coming to that clinical trial
has to accept though
that there's a one in four chance
that they may not receive any antiviral medication
but it is a trial.
It might be that these antiviral medications
have side effects we didn't anticipate.
It might be that combining two
of the antivirals, all it does is increase side effects.
And once we have this infrastructure of a trial set up,
if there are new antiviral medications
that have been developed in any part of the world,
we can slot them into this trial
and evaluate what is really the best way to go
in terms of treating this infection.
But given the accelerating rise
of confirmed COVID-19 infections,
no treatment can come fast enough.
The biggest challenge is time.
We have to do something now
to stop these epidemic curves rising so steeply.
And yet, even after mitigation efforts
to slow the spread of the virus,
official White House estimates released
at the end of March project between 100
and 240,000 American deaths.
And so physicians like David Wheeler consult
with colleagues to find something that works,
even with no scientifically proven treatment as of yet.
Nowadays, it seems like every new day
is like a new era.
Unwilling to simply wait
for the onslaught of patients,
as seen in China, Italy, Spain and New York,
they scour medical literature
on the hunt for lessons learned.
So in terms of the drugs that we pick,
it's a bit of all right,
what do we kind of think makes sense?
We'd like to do something rather than nothing
but we don't wanna hurt our patients
and so that's where we're trying
to strike that middle ground.
Do no harm but do something.
80% of those infected by the COVID-19 virus
likely won't need any medical care.
But limited medical resources
and the absence of verified effective treatments
means no one should be complacent.
It is gonna probably force a lot of hard decisions.
Some are gonna die, some may be left
with sort of lung complications afterwards and then others,
it's just gonna be a lot of work
to help get them through this.
(dramatic music)
Can't find what you're looking for?
Get subtitles in any language from opensubtitles.com, and translate them here.